Ariad Pharmaceuticals (ARIA) 6.34 $ARIA
SmarTrend Watching for Potential Rebound in Shares of Ariad Pharmaceuticals After 7.76% Loss
Comtex SmarTrend(R) - Thu Dec 11, 4:40PM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.34 to a high of $6.88. Yesterday, the shares fell 7.8%, which took the trading range below the 3-day low of $6.80 on volume of 13.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 6.34 (-0.13)
Energy Stocks Pare Gains as Crude Oil Closes Below $60 For First Time in Five Years
at The Street - Thu Dec 11, 1:52PM CST
Energy stocks are leading the markets higher, a day after they sparked a selloff.
SPLS: 16.47 (+0.37), DAL: 47.68 (-0.65), XOM: 86.60 (-2.60), COP: 62.45 (-1.16), LLY: 69.55 (-2.06), LULU: 52.95 (+1.99), LUV: 41.41 (-0.51), URBN: 32.06 (-0.23), EBAY: 55.77 (-1.01), AAL: 49.97 (-0.56), ODP: 7.79 (+0.25), ARIA: 6.34 (-0.13), CVX: 102.38 (-2.53), WAG: 74.50 (+1.49), XLE: 74.02 (-1.40)
Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 11, 12:19PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
AMBA: 46.33 (-1.64), LNCO: 11.03 (-0.36), MCEP: 6.50 (-0.07), LAKE: 10.79 (-0.40), CLDN: 17.25 (+0.75), BRID: 7.50 (+0.49), ARIA: 6.34 (-0.13), LINE: 12.01 (-1.32), MIND: 5.92 (+0.17), DGLY: 15.55 (+1.34), ALLT: 8.54 (+0.11), ROSE: 18.47 (-1.68)
Ariad slumps after analyst downgrade
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 9:25AM CST
IBB: 306.10 (-3.95), ARIA: 6.34 (-0.13)
Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action?
at The Street - Thu Dec 11, 8:14AM CST
Shares of Ariad Pharmaceuticals (ARIA) are down after Credit Suisse downgraded the global oncology company to 'underperform' from 'neutral' and lowered its price target to $6 from $8.
ARIA: 6.34 (-0.13)
Downgrade Alert for Ariad Pharmaceuticals (ARIA)
Comtex SmarTrend(R) - Thu Dec 11, 6:54AM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) was downgraded from Neutral to Underperform at Credit Suisse today. The stock closed yesterday at $7.02 on volume of 4.6 million shares, below average daily volume of 6.3 million. In the past 52 weeks, Ariad Pharmaceuticals share prices have been bracketed by a low of $3.80 and a high of $9.83 and closed yesterday at $7.02, 85% above that low price. Over the last five market days, the 200-day moving average (MA) has gone down 0.3% while the 50-day MA has advanced 1.5%.
ARIA: 6.34 (-0.13)
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 22.6% (ARIA)
Comtex SmarTrend(R) - Tue Dec 09, 5:08PM CST
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on October 29th, 2014 at $5.92. In approximately 1 month, Ariad Pharmaceuticals has returned 22.57% as of today's recent price of $7.25.
ARIA: 6.34 (-0.13)
Long-term follow up data for Iclusig positive
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 9:54AM CST
ARIA: 6.34 (-0.13)
ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia
Business Wire - Tue Dec 09, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced safety and efficacy follow-up data on Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in patients with a baseline T315I mutation from its Phase 1 and Phase 2 PACE trials in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
ARIA: 6.34 (-0.13)
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial
Business Wire - Tue Dec 09, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow up data from the Phase 1 trial of Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of four years in chronic phase CML (CP-CML) patients, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options and that responses have been maintained in CP-CML patients (n=43) with 72 percent having a major cytogenetic response (MCyR), 65 percent having a complete cytogenetic response (CCyR) and 56 percent having a major molecular response (MMR). Long-term safety data show that careful benefit-risk evaluations should guide decisions to use and maintain ponatinib therapy, particularly in patients who may be at increased risk for arterial thrombotic events.
ARIA: 6.34 (-0.13)
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
Business Wire - Mon Dec 08, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced long-term follow up from its pivotal Phase 2 trial of Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of approximately 3 years for chronic-phase CML (CP-CML) patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options. Deep and durable responses have been maintained in CP-CML patients with 83 percent of CP-CML patients who achieved a response, estimated to remain in major cytogenetic response (MCyR) at three years.
ARIA: 6.34 (-0.13)
Why Ariad Pharmaceuticals, Inc. Stock Catapulted 19% Higher in November
Sean Williams, The Motley Fool - Motley Fool - Fri Dec 05, 7:36AM CST
ARIA data by YCharts What: Shares of Ariad Pharmaceuticals , a biopharmaceutical company focused on developing therapies to treat cancer, surged by 19% in November according to data from S&P Capital IQ after reporting market-topping...
ARIA: 6.34 (-0.13)
ARIAD Pharmaceuticals (ARIA) Is Strong On High Volume Today
at The Street - Tue Dec 02, 9:00AM CST
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate
ARIA: 6.34 (-0.13)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 3.89 (-0.11), BIB: 128.83 (-3.16), INCY: 74.65 (-1.27), PFE: 30.95 (-0.70), IBB: 306.10 (-3.95), DRGS: 52.31 (-1.38), BIND: 5.82 (+0.02), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), ONTY: 2.02 (+0.31), ECYT: 6.25 (-0.06), BIS: 46.11 (+0.99), CLVS: 55.15 (+0.32), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), ARIA: 6.34 (-0.13), IRY: 47.43 (-0.71), IXJ: 101.03 (-1.47), FPRX: 22.13 (-1.12)
Most active Nasdaq-traded stocks
AP - Tue Nov 25, 5:58PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 34.00 (-1.19), GILD: 104.13 (-0.18), FB: 77.83 (+0.10), CMCSK: 55.11 (-0.50), ARIA: 6.34 (-0.13), ARCP: 8.99 (-0.24), MSFT: 46.95 (-0.22), INTC: 36.22 (-0.48), CMCSA: 55.35 (-0.55), AAPL: 109.73 (-1.89), CSCO: 26.85 (-0.14)
Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 8:25AM CST
Ariad Pharmaceuticals (ARIA) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
LCI: 43.58 (-0.46), VRX: 138.71 (-0.18), SCMP: 13.93 (-0.13), ARIA: 6.34 (-0.13)
Insider Trading Alerts for Hertz, Ariad Pharmaceuticals, J C Penney, Sirius XM, Apple, and Sunedison
PR Newswire - Tue Nov 25, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Hertz (NYSE:HTZ), Ariad Pharmaceuticals (NASDAQ:ARIA), J C Penney (NYSE:JCP), Sirius XM (NASDAQ:SIRI), Apple (NASDAQ:AAPL), and Sunedison (NYSE:SUNE).
HTZ: 21.33 (-1.01), SUNE: 18.55 (-0.47), JCP: 6.38 (+0.29), ARIA: 6.34 (-0.13), AAPL: 109.73 (-1.89), SIRI: 3.41 (-0.05)
SmarTrend Watching for Potential Rebound in Shares of Ariad Pharmaceuticals After 7.76% Loss
Comtex SmarTrend(R) - Thu Dec 11, 4:40PM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.34 to a high of $6.88. Yesterday, the shares fell 7.8%, which took the trading range below the 3-day low of $6.80 on volume of 13.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 6.34 (-0.13)
Energy Stocks Pare Gains as Crude Oil Closes Below $60 For First Time in Five Years
at The Street - Thu Dec 11, 1:52PM CST
Energy stocks are leading the markets higher, a day after they sparked a selloff.
SPLS: 16.47 (+0.37), DAL: 47.68 (-0.65), XOM: 86.60 (-2.60), COP: 62.45 (-1.16), LLY: 69.55 (-2.06), LULU: 52.95 (+1.99), LUV: 41.41 (-0.51), URBN: 32.06 (-0.23), EBAY: 55.77 (-1.01), AAL: 49.97 (-0.56), ODP: 7.79 (+0.25), ARIA: 6.34 (-0.13), CVX: 102.38 (-2.53), WAG: 74.50 (+1.49), XLE: 74.02 (-1.40)
Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 11, 12:19PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
AMBA: 46.33 (-1.64), LNCO: 11.03 (-0.36), MCEP: 6.50 (-0.07), LAKE: 10.79 (-0.40), CLDN: 17.25 (+0.75), BRID: 7.50 (+0.49), ARIA: 6.34 (-0.13), LINE: 12.01 (-1.32), MIND: 5.92 (+0.17), DGLY: 15.55 (+1.34), ALLT: 8.54 (+0.11), ROSE: 18.47 (-1.68)
Ariad slumps after analyst downgrade
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 9:25AM CST
IBB: 306.10 (-3.95), ARIA: 6.34 (-0.13)
Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action?
at The Street - Thu Dec 11, 8:14AM CST
Shares of Ariad Pharmaceuticals (ARIA) are down after Credit Suisse downgraded the global oncology company to 'underperform' from 'neutral' and lowered its price target to $6 from $8.
ARIA: 6.34 (-0.13)
Downgrade Alert for Ariad Pharmaceuticals (ARIA)
Comtex SmarTrend(R) - Thu Dec 11, 6:54AM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) was downgraded from Neutral to Underperform at Credit Suisse today. The stock closed yesterday at $7.02 on volume of 4.6 million shares, below average daily volume of 6.3 million. In the past 52 weeks, Ariad Pharmaceuticals share prices have been bracketed by a low of $3.80 and a high of $9.83 and closed yesterday at $7.02, 85% above that low price. Over the last five market days, the 200-day moving average (MA) has gone down 0.3% while the 50-day MA has advanced 1.5%.
ARIA: 6.34 (-0.13)
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 22.6% (ARIA)
Comtex SmarTrend(R) - Tue Dec 09, 5:08PM CST
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on October 29th, 2014 at $5.92. In approximately 1 month, Ariad Pharmaceuticals has returned 22.57% as of today's recent price of $7.25.
ARIA: 6.34 (-0.13)
Long-term follow up data for Iclusig positive
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 9:54AM CST
ARIA: 6.34 (-0.13)
ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia
Business Wire - Tue Dec 09, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced safety and efficacy follow-up data on Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in patients with a baseline T315I mutation from its Phase 1 and Phase 2 PACE trials in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
ARIA: 6.34 (-0.13)
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial
Business Wire - Tue Dec 09, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow up data from the Phase 1 trial of Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of four years in chronic phase CML (CP-CML) patients, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options and that responses have been maintained in CP-CML patients (n=43) with 72 percent having a major cytogenetic response (MCyR), 65 percent having a complete cytogenetic response (CCyR) and 56 percent having a major molecular response (MMR). Long-term safety data show that careful benefit-risk evaluations should guide decisions to use and maintain ponatinib therapy, particularly in patients who may be at increased risk for arterial thrombotic events.
ARIA: 6.34 (-0.13)
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
Business Wire - Mon Dec 08, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced long-term follow up from its pivotal Phase 2 trial of Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of approximately 3 years for chronic-phase CML (CP-CML) patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options. Deep and durable responses have been maintained in CP-CML patients with 83 percent of CP-CML patients who achieved a response, estimated to remain in major cytogenetic response (MCyR) at three years.
ARIA: 6.34 (-0.13)
Why Ariad Pharmaceuticals, Inc. Stock Catapulted 19% Higher in November
Sean Williams, The Motley Fool - Motley Fool - Fri Dec 05, 7:36AM CST
ARIA data by YCharts What: Shares of Ariad Pharmaceuticals , a biopharmaceutical company focused on developing therapies to treat cancer, surged by 19% in November according to data from S&P Capital IQ after reporting market-topping...
ARIA: 6.34 (-0.13)
ARIAD Pharmaceuticals (ARIA) Is Strong On High Volume Today
at The Street - Tue Dec 02, 9:00AM CST
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate
ARIA: 6.34 (-0.13)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 3.89 (-0.11), BIB: 128.83 (-3.16), INCY: 74.65 (-1.27), PFE: 30.95 (-0.70), IBB: 306.10 (-3.95), DRGS: 52.31 (-1.38), BIND: 5.82 (+0.02), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), ONTY: 2.02 (+0.31), ECYT: 6.25 (-0.06), BIS: 46.11 (+0.99), CLVS: 55.15 (+0.32), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), ARIA: 6.34 (-0.13), IRY: 47.43 (-0.71), IXJ: 101.03 (-1.47), FPRX: 22.13 (-1.12)
Most active Nasdaq-traded stocks
AP - Tue Nov 25, 5:58PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 34.00 (-1.19), GILD: 104.13 (-0.18), FB: 77.83 (+0.10), CMCSK: 55.11 (-0.50), ARIA: 6.34 (-0.13), ARCP: 8.99 (-0.24), MSFT: 46.95 (-0.22), INTC: 36.22 (-0.48), CMCSA: 55.35 (-0.55), AAPL: 109.73 (-1.89), CSCO: 26.85 (-0.14)
Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 8:25AM CST
Ariad Pharmaceuticals (ARIA) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
LCI: 43.58 (-0.46), VRX: 138.71 (-0.18), SCMP: 13.93 (-0.13), ARIA: 6.34 (-0.13)
Insider Trading Alerts for Hertz, Ariad Pharmaceuticals, J C Penney, Sirius XM, Apple, and Sunedison
PR Newswire - Tue Nov 25, 7:45AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Hertz (NYSE:HTZ), Ariad Pharmaceuticals (NASDAQ:ARIA), J C Penney (NYSE:JCP), Sirius XM (NASDAQ:SIRI), Apple (NASDAQ:AAPL), and Sunedison (NYSE:SUNE).
HTZ: 21.33 (-1.01), SUNE: 18.55 (-0.47), JCP: 6.38 (+0.29), ARIA: 6.34 (-0.13), AAPL: 109.73 (-1.89), SIRI: 3.41 (-0.05)
